P5394 - Patient Perceptions of Bowel Ultrasound: A Quantitative Evaluation of Satisfaction and Diagnostic Preference in IBD Care

Kacie H. Denton, MD, MPH¹, Audrey Bennett, MD², James C.. Slaughter, Dr.P.H.³, Elizabeth A. Scoville, MD, MSCI⁴, Robin L. Dalal, MD⁴, Sara Horst, MD, MPH, FACG², Dawn B. Beaulieu, MD, FACG⁴, David A. Schwartz, MD⁴, Baldeep Pabla, MD, MSCI⁴
1Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; 2Vanderbilt University School of Medicine, Nashville, TN; 3Vanderbilt University, Nashville, TN; 4Vanderbilt Inflammatory Bowel Disease Clinic, Nashville, TN

Introduction: Intestinal ultrasound (IUS) has been shown to be an accurate, non-invasive, point of care tool for monitoring disease activity in inflammatory bowel disease (IBD). While numerous studies have evaluated the diagnostic performance of IUS compared to other modalities, there is a notable gap in research related to patient perspectives on the role of IUS in IBD management.

Methods: This study employed a quantitatively driven mixed-methods design, combining a cross-sectional survey and retrospective chart review. A 21-question Likert scale (0-10) survey was administered to patients who underwent an IUS as part of their IBD clinic visit. Survey questions explored four domains of the patient perspective as it relates to IUS: 1.) patient experience of having an IUS performed 2.) patient preferences of IUS versus other modalities to monitor disease activity 3.) impact of IUS on the patient-provider relationship and 4.) role of IUS in enhancing patients’ understanding of their disease. Demographic and clinical data were extracted via chart review. Non-parametric comparisons were made to compare responses by demographic and clinical subgroups.

Results: A total of 57 patients completed the survey. Baseline demographics are shown in Table 1. Overall, patients reported a favorable experience with IUS (mean score: 9.15), preference of IUS over bloodwork, stool testing, CT or MRI, and colonoscopy (mean score: 7.64), positive patient-provider relationship (mean score: 8.07), and improved disease understanding (mean score: 7.74). The patient-provider relationship was enhanced more so in patients on steroids at the time of IUS than those not on steroids (8.70 vs 7.82, p = 0.03) and patient understanding was enhanced in patients with Crohn’s disease compared to ulcerative colitis (8.16 vs 7.18, p = .04).

Discussion: Patients reported high satisfaction with IUS, with consistently strong scores across all survey domains. Though small differences were seen in a few subgroups in selected domains, patients generally endorsed that IUS is well-tolerated, preferred over other diagnostic tests, enhances the patient-provider relationship, and improves their disease understanding. These results support the broader use of IUS as a preferred modality for IBD monitoring.


Figure: Table 1. Patient Demographics

Disclosures:
Kacie Denton indicated no relevant financial relationships.
Audrey Bennett: Celltrion – Consultant. Pfizer – Grant/Research Support.
James Slaughter indicated no relevant financial relationships.
Elizabeth Scoville indicated no relevant financial relationships.
Robin Dalal: AbbVie – Consultant.
Sara Horst: Abbvie – Consultant. Biocon – Consultant. Celltrion – Consultant. J&J – Consultant. Pfizer – Consultant. Takeda – Consultant.
Dawn Beaulieu: Abbvie – Advisory Committee/Board Member, Consultant. Bristol Myers Squibb – Consultant. Celltrion – Consultant. Institute of Functional Medicine – Consultant. Takeda – Advisory Committee/Board Member, Consultant.
David Schwartz: Abbvie – Consultant. Avobis – Consultant. Janssen – Consultant. Olympus – Consultant. Takeda – Consultant.
Baldeep Pabla: Astellas – Advisor or Review Panel Member. J&J – Advisory Committee/Board Member.

Kacie H. Denton, MD, MPH¹, Audrey Bennett, MD², James C.. Slaughter, Dr.P.H.³, Elizabeth A. Scoville, MD, MSCI⁴, Robin L. Dalal, MD⁴, Sara Horst, MD, MPH, FACG², Dawn B. Beaulieu, MD, FACG⁴, David A. Schwartz, MD⁴, Baldeep Pabla, MD, MSCI⁴. P5394 - Patient Perceptions of Bowel Ultrasound: A Quantitative Evaluation of Satisfaction and Diagnostic Preference in IBD Care, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.